Insight Medbotics unveiled Glenn, a next-generation surgical robotic system designed to help urologists treat prostate cancer.
Glenn leverages the company’s FDA-cleared IGAR technology. Toronto-based Insight Medbotics says IGAR is the first and only robotic system designed to work inside an MRI bore to garner this regulatory clearance. It features adaptability for future products that could move seamlessly across different care environments. Insight Medbotics says that includes moving from an MRI to a standard operating room or a physician’s office.
News: Brainlab unveils FDA-approved spine mixed reality navigation in US
According to the company, Glenn utilizes its previous work on MRI-compatible and clinically demonstrated robotics in breast biopsy. It digitizes the entire care pathway, offering new data-driven clinical insight. The company says Glenn gives urologists intuitive MRI access while removing the guesswork of traditional ultrasound guidance.
Over the past year, Insight Medbotics added leading urologists to its clinical advisory board. It also appointed Dr. Edward Matsumoto to its board of directors. Fazila Seker, Insight Medbot’s CEO and board member, says the clinicians’ needs drive the company’s design decisions and that access to the key opinion leaders can help advance the standard of care for prostate cancer patients.
“As we demonstrate the system to practicing urologists and collect their feedback on its design, they intuitively grasp its potential and express interest in acquiring it once it’s available,” said Seker. “The quick, precise, needle-based procedures it facilitates, such as biopsies and focal therapies, are of particular interest. They also noted that it would eliminate the need for rectal probes, which some said their patients wish to avoid.”
“As we develop full functionality with our prostate platform, our focus is addressing urologists’ need to access MRI for their patients. That means advancing Glenn toward regulatory approval, beginning with the U.S. market and following in Canada and other countries.”
Glenn remains under development and not approved by any regulatory body.
